Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
  • C07D487/14—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the invention relates to compounds, compositions and methods for treating cognitive impairment associated with central nervous system (CNS) disorders, cognitive impairment associated with brain cancers, and brain cancers in a subject in need thereof.
• CNS central nervous system
• Cognitive ability may decline as a normal consequence of aging or as a consequence of a central nervous disorder.
• MCI Mild Cognitive Impairment
• AAMI Age- Associated Memory Impairment
• ARCD Age-Related Cognitive Decline
• Cognitive impairment is also associated with other central nervous system (CNS) disorders, such as dementia, Alzheimer’s Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder (in particular, mania), amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson’s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.
• CNS central nervous system
• AD Alzheimer’s Disease
• prodromal AD post traumatic stress disorder
• PTSD post traumatic stress disorder
• ALS amyotrophic lateral sclerosis
• cancer-therapy-related cognitive impairment mental retardation
• Parkinson’s disease PD
• autism spectrum disorders fragile X disorder
• Rett syndrome compulsive behavior
• substance addiction substance addiction
• GABAA receptors are pentameric assemblies from a pool of different subunits (al-6, b1-3, g1-3, d, e, p, q) that form a Cl- permeable channel that is gated by the neurotransmitter g-aminobutyric acid (GABA).
• GABA neurotransmitter g-aminobutyric acid
• Various pharmacological effects including anxiety disorders, epilepsy, insomnia, pre-anesthetic sedation, and muscle relaxation, are mediated by different GABAA subtypes.
• A is C, CR 6 , or N;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
• D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• R 2 is -OR 8 , -SR 8 , -(CH 2 ) n OR 8 , -(CH 2 ) n O(CH 2 ) n R 8 , -(CH 2 ) P R 8 and -(CH 2 ) n N(R”)R 10 ; and wherein R 2 is independently substituted with 0-5 R’;
• n and n are independently integers selected from 0-4;
• p is an integer selected from 2-4;
• each occurrence of the bond“ ” is either a single bond or a double bond
• R 1 , R 2 , R 4 , and R 5 are each independently selected from:
• R 3 is absent or is selected from:
• each R 6 is independently -H or -(Cl-C6)alkyl
• each R 7 is independently -H or -(Cl-C6)alkyl
• each R 8 is independently -(Cl-C6)alkyl, -(C3-Cl0)-cycloalkyl, (C6-Cl0)-aryl, or 5- to 10- membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0-5 R’; each R 10 is independently -(C3-Cl0)-cycloalkyl, 3- to 10- membered heterocyclyl-,
• each occurrence of R 10 is independently substituted with 0-5 R’; each R is independently selected from:
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2 , wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3- Cl0)cycloalkyl, or a 3 - to 10- membered heterocyclyl; wherein each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -NO2, -NCS, -CN, -CF 3 , -OCF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)-alkyl-, (C6-C10)- aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)-alkyl-, and (C6-C10)- aryl-0-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-3 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH 2 OR°, -CH 2 NR°
• R° is independently selected from: -(Cl-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, and (C6-Cl0)-aryl-.
• A is C, CR 6 , or N;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
• D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• n R 2 is independently substituted with 0-5 R’; m and n are independently integers selected from 0-4;
• p is an integer selected from 2-4;
• each occurrence of the bond“ ” is either a single bond or a double bond
• R 1 , R 2 , R 4 , and R 5 are each independently selected from:
• R 3 is absent or is selected from:
• each R 7 is independently -H or -(Cl-C6)alkyl
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• each occurrence of R is independently substituted with 0-5 R’; or when two R groups bound to the same atom, the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2 , wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3-
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -NO2, -NCS, -CN, -CF 3 , -OCF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, (C3-
• C6)-cycloalkyl 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6- Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)-alkyl-, (C6-ClO)-aryl-(Cl-C6)- alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)-alkyl-, and (C6-ClO)-aryl-0-(Cl- C6)-alkyl-. [0013]
• A is C, CR 6 , orN;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N; D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• n are each independently an integer selected from 0-4;
• each occurrence of the bond“ ” is either a single bond or a double bond
• R 1 , R 2 , R 4 , and R 5 are each independently selected from:
• R 3 is absent or is selected from:
• each R 6 is independently -H or -(Cl-C6)alkyl
• each R 7 is independently -H or -(Cl-C6)alkyl
• each R 8 is independently -(Cl-C6)alkyl, -(C3-Cl0)-cycloalkyl, -(C6-Cl0)-aryl, or 5- to 10- membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0-5 R’;
• each R is independently selected from:
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2 , wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3- Cl0)cycloalkyl, or a 3 - to 10- membered heterocyclyl;
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -N0 2 , -NCS, -CN, -CF 3 , -0CF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, (C3-
• C6)-cycloalkyl 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)-alkyl-,
• the present invention provides a compound of formula II:
• the present invention provides a compound of formula III:
• the present invention provides a compound of formula IV:
• R 2 is -OR 8 , -SR 8 , or -(CH 2 ) n OR 8 , wherein R 2 is independently substituted with 0-5 R’ and wherein m, n, R 1 , R 3 , R 4 , R 5 , R 6 , and R 8 are as defined in formula I.
• the present invention provides a compound of formula IV:
• R 2 is -(CH 2 ) n O(CH 2 ) n R 8 , -(CH 2 ) P R 8 or
• the present invention provides a compound of formula V:
• A is C, CR 6 , or N;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
• D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• R 2 is independently substituted with 0-5 R’;
• n and n are independently integers selected from 0-4;
• p is an integer selected from 2-4;
• each occurrence of R 8 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl; wherein each R 8 excluding -H and -(C1-C6) alkyl is independently substituted by 0-5 of -halogen, -(C1-C6) alkyl, -CF3, -OCF3, or 0-(Cl-C6) alkyl;
• R 3 is absent or is selected from:
• each of R 9 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered heteroaryl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C1-C6) alkyl-5- 10 membered heteroaryl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -C(0)-(C6-ClO) aryl, , wherein each R 9 is independently substituted with 0-5 R 11 ; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OCF 3 , -OMe, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 10 is selected from -H, -(C1-
• each R 7 is independently -H or -(Cl-C6)alkyl
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2 , wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3- Cl0)cycloalkyl, or a 3 - to 10- membered heterocyclyl; wherein each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -NO2, -NCS, -CN, -CF 3 , -OCF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)- alkyl-, (C6-ClO)-aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)- alkyl-, and (C6-Cl0)-aryl-O-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-3 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH2OR 0 , -CH 2 N(R°) 2 , -Cl-
• the present invention provides a compound of formula V-a:
• A is C, CR 6 , or N;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
• D is N, NR 7 , 0, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• R 2 is independently substituted with 0-5 R’;
• n and n are independently integers selected from 0-4;
• p is an integer selected from 2-4;
• each occurrence of the bond“ ” is either a single bond or a double bond
• R 1 , R 2 , R 4 , and R 5 are each independently selected from:
• each occurrence of R 8 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl;
• each R 8 excluding -H and -(C1-C6) alkyl is independently substituted by 0-5 of -halogen, -(C1-C6) alkyl, -CF3, -OCF3, or 0-(Cl-C6) alkyl;
• R 3 is absent or is selected from:
• each R 9 is independently substituted with 0-5 R 11 ; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OH, - OCF 3 , OCHF2, -0-(Cl-C6)alkyl, -0-CH 2 -(C3-C6)cycloalkyl, -CN, -SCH3 -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 10 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered heteroaryl, -(C3-C6) cycloalkyl, -CH 2 -(C3-C6) cycloalkyl, -CH 2 -(C6-ClO) aryl, and - CH 2 -5-lO-membered heteroaryl, wherein each R 10 is independently substituted
• each R 7 is independently -H or -(Cl-C6)alkyl
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3- Cl0)cycloalkyl, or a 3- to 10- membered heterocyclyl;
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -NO2, -NCS, -CN, -CF 3 , -OCF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)- alkyl-, (C6-ClO)-aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)- alkyl-, and (C6-Cl0)-aryl-O-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-3 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH2OR 0 , -CH 2 N(R°) 2, -C(0)N
• R° is independently selected from: -(Cl-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to lO-membered heteroaryl-, and (C6-Cl0)-aryl-.
• R° is independently selected from: -(Cl-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to lO-membered heteroaryl-, and (C6-Cl0)-aryl-.
• each R 1 is independently selected from: -halogen, -OMe, -CoC-R 8 , -CN, -CHF 2 , -
• R 8 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl; wherein each R 8 excluding -H and -(C1-C6) alkyl, -(C6-C10) aryl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl; wherein each R 8 excluding -H and -(C1-C6) alkyl
• R 2 is -halogen, -(CR 2 ) I -3-OR, -(CR 2 ) I.3 -0(CR 2 ) I.3 -R, -H, -(C1-C6) alkyl, -(C6-C10) aryl, (C6-C10) aryl-(Cl-C6) alkyl-, -5-10 membered heteroaryl, 5-10 membered heteroaryl-(Cl-C6) alkyl-, or -OR 9 ; wherein each occurrence of R is independently selected from -H, -(C1-C6) alkyl, (C6- C10) aryl-, -5- to 10- membered heteroaryl, (C6-ClO)-aryl-(Cl-Cl2) aliphatic-, 5-10 membered heteroaryl -(C6-C 10) alkyl-, or -(C3-C6) cycloalkyl; wherein each R excluding -H
• heteroaryl -(C1-C6) alkyl-(C6-ClO) aryl, -(C1-C6) alkyl-5- 10 membered heteroaryl, -(C3-C6) cycloalkyl, and -(C1-C6) alkyl-(C3-C6) cycloalkyl; wherein each R 9 is independently substituted with 0-5 R 11 ; wherein each occurrence of R 11 is independently selected from -halogen, -CF3, -OCF3, - OMe, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl,
• R 3 is selected from: -halogen, -CN, -CoCR 9 , COOMe, -COOEt, -(C1-C6) alkyl-CoC-R 10 , -CHi-O-R 10 , -CH 2 -0-CH 2 -R 10
• R 9 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• each R 9 is independently substituted with 0-5 R 11 ; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OCF 3 , - OMe, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 10 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• heteroaryl -(C3-C6) cycloalkyl, -CH 2 -(C3-C6) cycloalkyl, -CFh-(C6-ClO) aryl, and - CH 2 -5-lO-membered heteroaryl, wherein each R 10 is independently substituted with 0-5 R’; wherein R 7 is selected from -(Cl-C6)alkyl, -(C3-C6)cycloalkyl, -5 to 10 membered
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -NO2, -NCS, -CN, -CF 3 , -OCF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)- alkyl-, (C6-ClO)-aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)- alkyl-, or (C6-Cl0)-aryl-O-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-5 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH 2 OR°, -CH 2 N(R°) 2 , -C(0)N
• the present invention provides a compound of formula VII:
• each R 1 is independently selected from: -halogen, -OMe, -CoC-R 9 , -CN, -CHF 2 , -
• R 9 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl; wherein each R 9 excluding -H and -(C1-C6) alkyl, -(C6-C10) aryl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl; wherein each R 9 excluding -H and -(C1-C6) alkyl
• R 2 is -(CH 2 ) n OR 8 , or -(CH 2 ) n O(CH 2 ) n R 8 , wherein each occurrence of R 8 is independently -H, -(Cl-C6)alkyl, -(C6-Cl0)-aryl, 5- to 10- membered heteroaryl-, 5-10 membered heteroaryl-(Cl-C6) alkyl-, -(C3-C6)cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, or - (C1-C6) alkyl -(C3-C6) cycloalkyl;
• each R 8 excluding -H and -(C1-C6) alkyl is independently substituted by 0-5 of -halogen, -(C1-C6) alkyl, -CF 3 , -OCF 3 , or -0-(Cl-C6) alkyl; wherein n is an integer from 0-4; wherein R 2 is independently substituted with 0-5 R’;
• R 3 is selected from: -halogen, -CN, -CoCR 9 , COOMe, -COOEt, -(Cl-C6)alkyl-CoC-R 10 , -CH2-O-R 10 , -CH2-O-CH2-R 10
• R 9 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• heteroaryl -(C1-C6) alkyl-(C6-ClO) aryl, -(C1-C6) alkyl-5- 10 membered heteroaryl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, and -C(0)-(C6-ClO) aryl; wherein each R 9 is independently substituted with 0-5 R 11 ; wherein R 10 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• each R 10 is independently substituted with 0-5 R’; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OCF 3 , - OMe, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 7 is selected from -(Cl-C6)alkyl, -(C3-C6)cycloalkyl, -5 to 10 membered
• heteroaryl -(C6-C10) aryl, -(C6-ClO)aryl-(Cl-C6)alkyl, and -5 to 10 membered heteroaryl-(Cl-C6)alkyl, and -5-10 membered heteroaryl; wherein each R 7 is independently substituted with 0-5 R’; wherein R 3 is substituted with 0-5 R’; each occurrence of R 4 and R 5 is independently -H or -(Cl-C6)alkyl;
• each R 6 is independently -H or -(Cl-C6)alkyl
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -N0 2 , -NCS, -CN, -CFS, -OCF3 and
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)- alkyl-, (C6-ClO)-aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)- alkyl-, and (C6-Cl0)-aryl-O-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-5 R 1 independently selected from: halogen, - R°, -OR 0 , oxo, -CH 2 OR°,
• R° is independently selected from:
• the present invention provides a compound of formula VIII:
• n 0-3;
• each R 1 is independently selected from: -halogen, -OMe, -CoC-R 8 , -CHF 2 , -CF 3 , -OCF 3 , wherein R 8 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl; wherein each R 8 excluding -H and -(C1-C6) alkyl is independently substituted by 0-5 of -halogen, -(C1-C6) alkyl, -CF3, -OCF3, or 0-(Cl-C6) alkyl;
• R 2 is -H, -CH 2 -OR, CH S , CH 2 -phenyl; wherein each occurrence of R is independently selected from -(C1-C6) alkyl, (C6- C10) aryl-, -5- to 10- membered heteroaryl, (C6-ClO)-aryl-(Cl-Cl2) aliphatic-, 5-10 membered heteroaryl -(C6-C 10) alkyl-, or -(C3-C6) cycloalkyl; wherein each R excluding -H and -(C1-C6) alkyl is independently substituted by 0-5 of -halogen, -(C 1 -C6) alkyl, -CF3, -OCF3, or -0-(C 1 -C6) alkyl, wherein each occurrence of R 11 is independently selected from -halogen, -CF3, -OCF3, - OMe, -(C6-C10) aryl, -
• R 3 is selected from: -CoCR 9 , -(C1-C6) alkyl -CoC-R 10 , -CH 2 -0-R 10 , wherein R 9 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• each R 9 is independently substituted with 0-5 R 11 ; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OCF 3 , - OMe, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 10 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• heteroaryl -(C3-C6) cycloalkyl, -CH 2 -(C3-C6) cycloalkyl, -CH 2 -(C6-ClO) aryl, and - CH 2 -5-lO-membered heteroaryl, wherein each R 10 is independently substituted with 0-5 R’; wherein R 7 is selected from -(Cl-C6)alkyl, -(C3-C6)cycloalkyl, -5 to 10 membered
• heteroaryl -(C6-C10) aryl, -(C6-ClO)aryl-(Cl-C6)alkyl, and -5 to 10 membered heteroaryl-(Cl-C6)alkyl, and -5-10 membered heteroaryl; wherein each R 7 is independently substituted with 0-5 R’;
• each occurrence of R 4 and R 5 is independently -H, -(Cl-C6)alkyl, or -(C1-C6) alkyl-(C6- C10) aryl; the (C6-C10) aryl being independently substituted with 0-5 -halogen; each R 6 is independently -H or -(Cl-C6)alkyl.
• the present invention provides a compound of formula IX:
• each R 1 is independently selected from: -Cl, -OMe, -CoC-R 9 , -CHF 2 , -CF 3 , and -OCF3; wherein R 9 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl;
• each R 9 excluding -H and -(C1-C6) alkyl is independently substituted by 0-5 of -halogen, -(C1-C6) alkyl, -CF3, -OCF3, or 0-(Cl-C6) alkyl;
• R 2 is -H, CH2OR 8 , CFF, CFh-phenyl, wherein each occurrence of R 8 is independently -H, -(Cl-C6)alkyl, -(C6-Cl0)-aryl, 5- to 10- membered heteroaryl-, 5-10 membered heteroaryl-(Cl-C6) alkyl-, -(C3-C6)cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, or - (C1-C6) alkyl -(C3-C6) cycloalkyl;
• each R 8 excluding -H and -(C1-C6) alkyl is independently substituted by 0-5 of -halogen, -(C1-C6) alkyl, -CF3, -OCF3, or -0-(Cl-C6) alkyl;
• R 3 is selected from: -CoCR 9 , -(Cl-C6)alkyl-CoC-R 10 ,
• R 9 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• heteroaryl -(C1-C6) alkyl-(C6-ClO) aryl, -(C1-C6) alkyl-5- 10 membered heteroaryl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, and -C(0)-(C6-ClO) aryl; wherein each R 9 is independently substituted with 0-5 R 11 ; wherein R 10 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• each R 10 is independently substituted with 0-5 R’; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OCF 3 , - OMe, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 7 is selected from -(Cl-C6)alkyl, -(C3-C6)cycloalkyl, -5 to 10 membered
• heteroaryl -(C6-C10) aryl, -(C6-ClO)aryl-(Cl-C6)alkyl, and -5 to 10 membered heteroaryl-(Cl-C6)alkyl, and -5-10 membered heteroaryl; wherein each R 7 is independently substituted with 0-5 R’; wherein R 3 is substituted with 0-5 R’; each occurrence of R 4 and R 5 is independently -H or -(Cl-C6)alkyl;
• each R 6 is independently -H or -(Cl-C6)alkyl.
• the present invention provides a compound formula X:
• each R 1 is independently selected from: -halogen, -(C6-Cl0)aryl, -OMe, -CN, -CoC-R 8 , - CHF 2 , -CF B , and -OCF 3 , OCHF 2 , -(C1-C6) alkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -5-10 membered heteroaryl, -(C1-C6) alkyl-5-l0 membered heteroaryl, and -(C3-C6) cycloalkyl; wherein R 8 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10)
• R 2 is -H, -CH2R 8 , -CFb, -CH2-OR 8 , wherein each occurrence of R 8 is independently -H, - (Cl-C6)alkyl, -(C6-Cl0)-aryl, 5- to 10- membered heteroaryl-, 5-10 membered heteroaryl-(Cl-C6) alkyl-, -(C3-C6)cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, or - (C1-C6) alkyl -(C3-C6) cycloalkyl;
• each R 8 excluding -H and -(C1-C6) alkyl is independently substituted with 0- 5 of -halogen, -(C1-C6) alkyl, -CF3, -OCF3, or -0-(Cl-C6) alkyl;
• R 3 is selected from: -CoCR 9 , -(Cl-C6)alkyl-CoC-R 10 , -CH2-O-R 10 , -CH2-O-CH2-R 10 ,
• each 5-member heterocycle or heteroaryl is substituted with 0-4 R 7 ; wherein R 9 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• heteroaryl benzyl cyclopropyl, -(C1-C6) alkyl -(C6-C 10) aryl, -(C1-C6) alkyl-5- 10 membered heteroaryl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, and - C(0)-(C6-ClO) aryl, 5-10 membered heterocycle,
• each R 9 is independently substituted with 0-5 R 11 ; wherein R 10 is selected from -H, -halogen, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10
• each R 10 is independently substituted with 0-5 R’; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OCF 3 , - OMe, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 7 is selected from -(Cl-C6)alkyl, -(C3-C6)cycloalkyl, -5 to 10 membered
• heteroaryl -(C6-C10) aryl, -(C6-ClO)aryl-(Cl-C6)alkyl, and -5 to 10 membered heteroaryl-(Cl-C6)alkyl, and -5-10 membered heteroaryl; wherein each R 7 is independently substituted with 0-5 R’; wherein R 3 is substituted with 0-5 R’; wherein R’ is selected from -Cl, -F, -(Cl-C6)alkyl, -OMe, and -(C6-Cl0)aryl; each occurrence of R 4 and R 5 is independently -H or -(Cl-C6)alkyl;
• each R 6 is independently -H or -(Cl-C6)alkyl.
• the present invention provides compound of formula X-a:
• each R 1 is independently selected from: -halogen, -(C6-Cl0)aryl, -OMe, -CN, -CoC-R 8 , - CHF 2 , -CF B , and -OCF 3 , -OCHF 2 , -(C1-C6) alkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -5- 10 membered heteroaryl, -(C1-C6) alkyl-5-l0 membered heteroaryl, and -(C3-C6) cycloalkyl; wherein R 8 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C
• R 2 is -H, -CH 2 R 8 , -CH 3 , -CH 2 -OR 8 , wherein each occurrence of R 8 is independently -H, - (Cl-C6)alkyl, -(C6-Cl0)-aryl, 5- to 10- membered heteroaryl-, 5-10 membered heteroaryl-(Cl-C6) alkyl-, -(C3-C6)cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, or - (C1-C6) alkyl -(C3-C6) cycloalkyl;
• each R 8 excluding -H and -(C1-C6) alkyl is independently substituted with 0- 5 of -halogen, -(C1-C6) alkyl, -CF3, -OCF3, or -0-(Cl-C6) alkyl;
• R 3 is selected from: -CoCR 9 , -(Cl-C6)alkyl-CoC-R 10 , -CH2-O-R 10 , -CH2-O-CH2-R 10 ,
• each 5-member heterocycle or heteroaryl is substituted with 0-4 R 7 ; wherein R 9 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• heteroaryl benzyl cyclopropyl, -(C1-C6) alkyl -(C6-C 10) aryl, -(C1-C6) alkyl-5- 10 membered heteroaryl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, and - C(0)-(C6-ClO) aryl, 5-10 membered heterocycle,
• each R 9 is independently substituted with 0-5 R 11 ; wherein R 10 is selected from -H, -halogen, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10
• each R 10 is independently substituted with 0-5 R’; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OH, - OCF 3 , -OCHF 2 , -0(Cl-C6)alkyl, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 7 is selected from -(Cl-C6)alkyl, -(C3-C6)cycloalkyl, -5 to 10 membered
• heteroaryl -(C6-C10) aryl, -(C6-ClO)aryl-(Cl-C6)alkyl, and -5 to 10 membered heteroaryl-(Cl-C6)alkyl, and -5-10 membered heteroaryl; wherein each R 7 is independently substituted with 0-5 R’; wherein R 3 is substituted with 0-5 R’; wherein R’ is selected from -Cl, -F, -(Cl-C6)alkyl, -OMe, and -(C6-Cl0)aryl;
• each occurrence of R 4 and R 5 is independently -H or -(Cl-C6)alkyl
• each R 6 is independently -H or -(Cl-C6)alkyl.
• the present invention provides a compound of formula
• each R 1 is independently selected from: -halogen, -OMe, -CoC-R 8 , -CN, -CHF 2 , -CF 3 , and -OCF3, (C6-Cl0)aryl, -(Cl-C6)alkyl-(C6-ClO)aryl;
• R 8 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl;
• each R 8 excluding -H and -(C1-C6) alkyl is independently substituted by 0-5 of -halogen, -(C1-C6) alkyl, -CF3, -OCF3, or 0-(Cl-C6) alkyl;
• R 2 is CH 2 OR 8 , CH 3 , -OR 8 , CFh-phenyl, wherein each occurrence of R 8 is independently -H, -(Cl-C6)alkyl, -(C6-Cl0)-aryl, 5- to 10- membered heteroaryl-, 5-10 membered heteroaryl-(Cl-C6) alkyl-, -(C3-C6)cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, or - (C1-C6) alkyl -(C3-C6) cycloalkyl;
• each R 8 excluding -H and -(C1-C6) alkyl is independently substituted with 0-5 of -halogen, -(C1-C6) alkyl, -CF3, -OCF3, or -0-(Cl-C6) alkyl;
• R 9 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• heteroaryl -(C1-C6) alkyl-(C6-ClO) aryl, -(C1-C6) alkyl-5- 10 membered heteroaryl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, and -C(0)-(C6-ClO) aryl, - 5-10 membered heterocycle,
• each R 9 is independently substituted with 0-5 R 11 ; wherein R 10 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• each R 10 is independently substituted with 0-5 R’; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OCF 3 , - OMe, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 7 is selected from -(Cl-C6)alkyl, -(C3-C6)cycloalkyl, -5 to 10 membered heteroaryl, -(C6-C10) aryl, -(C6-ClO)aryl-(Cl-C6)alkyl, and -5 to 10 membered heteroaryl-(C
• each R 7 is independently substituted with 0-5 R’;
• R 3 is substituted with 0-5 R’
• each occurrence of R 4 and R 5 is independently -H or -(Cl-C6)alkyl
• each R 6 is independently -H or -(Cl-C6)alkyl.
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -N0 2 , -NCS, -CN, -CF 3 , -0CF3 and
• the invention provides a compound of formula Xl-a:
• each R 1 is independently selected from: -halogen, -OMe, -CoC-R 8 , -CN, -CHF 2 , -CF 3 , and -OCF 3 , (C6-Cl0)aryl, -(Cl-C6)alkyl-(C6-ClO)aryl;
• R 8 is -H, -(C1-C6) alkyl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, -(C6-C10) aryl, -5-10 membered heteroaryl, or -(C1-C6) alkyl-5-l0 membered heteroaryl;
• each R 8 excluding -H and -(C1-C6) alkyl is independently substituted by 0-5 of -halogen, -(C1-C6) alkyl, -CF 3 , -OCF 3 , or 0-(Cl-C6) alkyl;
• R 2 is CFhOR 8 , CH 3 , -OR 8 , CH 2 -phenyl, wherein each occurrence of R 8 is independently -H, -(Cl-C6)alkyl, -(C6-Cl0)-aryl, 5- to 10- membered heteroaryl-, 5-10 membered heteroaryl-(Cl-C6) alkyl-, -(C3-C6)cycloalkyl, -(C1-C6) alkyl-(C6-ClO) aryl, or - (C1-C6) alkyl -(C3-C6) cycloalkyl;
• each R 8 excluding -H and -(C1-C6) alkyl is independently substituted with 0-5 of -halogen, -(C1-C6) alkyl, -CF 3 , -OCF 3 , or -0-(Cl-C6) alkyl;
• R 9 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• heteroaryl -(C1-C6) alkyl-(C6-ClO) aryl, -(C1-C6) alkyl-5- 10 membered heteroaryl, -(C3-C6) cycloalkyl, -(C1-C6) alkyl-(C3-C6) cycloalkyl, and -C(0)-(C6-ClO) aryl, - 5-10 membered heterocycle,
• each R 9 is independently substituted with 0-5 R 11 ; wherein R 10 is selected from -H, -(C1-C6) alkyl, -(C6-C10) aryl, -5-10 membered
• each R 10 is independently substituted with 0-5 R’; wherein each occurrence of R 11 is independently selected from -halogen, -CF 3 , -OCF 3 , - OCF2H -0-(Cl-C6)alkyl, -(C6-C10) aryl, -(Cl-C6)alkyl, and -5 to 10 membered heteroaryl, wherein R 7 is selected from -(Cl-C6)alkyl, -(C3-C6)cycloalkyl, -5 to 10 membered
• heteroaryl -(C6-C10) aryl, -(C6-ClO)aryl-(Cl-C6)alkyl, and -5 to 10 membered heteroaryl-(Cl-C6)alkyl, and -5-10 membered heteroaryl; wherein each R 7 is independently substituted with 0-5 R’; wherein R 3 is substituted with 0-5 R’; each occurrence of R 4 and R 5 is independently -H or -(Cl-C6)alkyl;
• each R 6 is independently -H or -(Cl-C6)alkyl.
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -NO2, -NCS, -CN, -CF 3 , -OCF3 and
• the present invention also provides pharmaceutical compositions that comprise a compound of formulae I, II, III, IV, V, V-a, VI, VII, VIII, IX, X, X-a, XI, or CI-a or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
• compounds of formula I are GABAA a5 receptor positive allosteric modulators.
• compounds of formula II are GABAA a5 receptor positive allosteric modulators.
• compounds of formula III are GABAA a5 receptor positive allosteric modulators.
• compounds of formula IV are GABAA a5 receptor positive allosteric modulators.
• compounds of formula V are GABAA a5 receptor positive allosteric modulators.
• compounds of formula V-a are GABAA a5 receptor positive allosteric modulators.
• compounds of formula VI are GABAA a5 receptor positive allosteric modulators.
• compounds of formula VII are GABAA a5 receptor positive allosteric modulators.
• compounds of formula VIII are GABAA a5 receptor positive allosteric modulators.
• compounds of formula IX are GABAA a5 receptor positive allosteric modulators.
• compounds of formula X are GABAA a5 receptor positive allosteric modulators.
• compounds of formula X-a are GABAA a5 receptor positive allosteric modulators.
• compounds of formula VI are GABAA a5 receptor positive allosteric modulators.
• compounds of formula CI-a are GABAA a5 receptor positive allosteric modulators.
• Compounds of formula I, II, III, IV, V, V-a, VI, VII, VIII, IX, X, X-a, XI, or CI-a can be used to treat the conditions described herein, such as through activity as GABAA a5 receptor positive allosteric modulators.
• a method for treating cognitive impairment associated with a CNS disorder in a subject in need of treatment or at risk of said cognitive impairment comprising the step of administering to said subject a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
• the CNS disorder with cognitive impairment includes, without limitation, age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer’s Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson’s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.
• MCI Mild Cognitive Impairment
• aMCI amnestic MCI
• AAMI Age-Associated Memory Impairment
• ARCD Age Related Cognitive Decline
• AD Alzheimer’s Disease
• PTSD post traumatic stress disorder
• schizophrenia bipolar disorder
• PD dementia
• ALS amyotrophic lateral sclerosis
• PD mental retardation
• autism spectrum disorders fragile X disorder
• a method of preserving or improving cognitive function in a subject in need thereof comprising the step of administering to said subject a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
• a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof is administered every 12 or 24 hours.
• a method for treating brain cancers comprising the step of administering to said subject a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
• a method of preserving or improving cognitive function in a subject suffering from brain cancers comprising the step of administering to said subject a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
• a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof is administered every 12 or 24 hours.
• a method for treating Parkinson’s disease psychosis comprising the step of administering to said subject a therapeutically effective amount of a compound of the invention or a
• a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof is administered every 12 or 24 hours.
• the compounds and compositions of the present invention are for use as a medicament. In some embodiments, the compounds and compositions of the present invention are for use in treating cognitive impairment associated with a CNS disorder in a subject in need of treatment or at risk of said cognitive impairment.
• the CNS disorder with cognitive impairment includes, without limitation, age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer’s Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson’s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.
• the compounds and compositions of the present invention are for use as a medicament in treating brain cancers (including brain tumors, e.g., medulloblastomas).
• the compounds and compositions of the present invention are for use as a medicament in treating brain cancers (including brain tumors, e.g., medulloblastomas).
• the compounds and compositions of the present invention are for use as a medicament in treating brain cancers (including
• compositions of the present invention are for use as a medicament in treating cognitive impairment associated with brain cancers (including brain tumors, e.g.,
• the compounds and compositions of the present invention are for use as a medicament in treating Parkinson’s disease psychosis.
• this application provides the use of a compound or composition described herein in the preparation of a medicament for the treatment of cognitive impairment associated with a CNS disorder in a subject in need of treatment or at risk of said cognitive impairment.
• the CNS disorder with cognitive impairment includes, without limitation, age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory
• the compounds and compositions of the present invention are for use in the preparation of a medicament for the treatment of brain cancers (including brain tumors, e.g., medulloblastomas).
• brain cancers including brain tumors, e.g., medulloblastomas.
• the compounds and compositions of the present invention are for use in the preparation of a medicament for the treatment of brain cancers (including brain tumors, e.g., medulloblastomas).
• the compounds and compositions of the present invention are for use in the preparation of a medicament for the treatment of brain cancers (including brain tumors, e.g., medulloblastomas).
• compositions of the present invention are for use in the preparation of a medicament for the treatment of cognitive impairment associated with brain cancers (including brain tumors, e.g., medulloblastomas).
• brain cancers including brain tumors, e.g., medulloblastomas.
• compositions of the present invention are for use in the preparation of a medicament for the treatment of Parkinson’s disease psychosis.
• Figure 1 is a graph depicting the effects of administering methyl 3,5- diphenylpyridazine-4-carboxylate on the spatial memory retention of ten aged-impaired (AI) rats in an eight-arm Radial Arm Maze (RAM) test.
• the black bars refer to rats treated with vehicle alone; open bars refer to rats treated with methyl 3,5- diphenylpyridazine-4-carboxylate at different doses; hatched bar refers to rats treated with the combination of TB21007 and methyl 3,5-diphenylpyridazine-4-carboxylate.
• Figure 2 is a graph showing the effect of methyl 3,5-diphenylpyridazine-4- carboxylate (administered intravenously) on the binding of Rol545 l3 in the
• FIG. 3 is a graph showing dose-dependent GABAA a5 receptor occupancy by methyl 3,5-diphenylpyridazine-4-carboxylate administered intravenously, with receptor occupancy determined either by the ratio between hippocampus (a region of high GABAA a5 receptor density) exposure of RO 15-4513 and cerebellum (a region with low GABAA a5 receptor density) exposure of RO 15-4513, or by using the GABAA a5 selective compound L-655,708 (10 mg/kg, i.v.) to define full occupancy.
• Figure 4 is a graph showing exposure occupancy relationships for methyl 3,5- diphenylpyridazine-4-carboxylate in hippocampus. Methyl 3,5-diphenylpyridazine-4- carboxylate occupies about 32% of GABAA a5 receptors at exposures which are behaviorally active in aged-impaired rats.
• Figures 5 is a graph depicting the effect of ethyl 3-methoxy-7-methyl-9H- benzo[f]imidazo[l,5-a][l,2,4]triazolo[4,3-d][l,4]diazepine-l0-carboxylate on the spatial memory retention of ten aged-impaired (AI) rats in an eight-arm Radial Arm Maze (RAM) test.
• Figure 5 shows the effect of ethyl 3-methoxy-7-methyl-9H- benzo[f]imidazo[l,5-a][l,2,4]triazolo[4,3-d][l,4]diazepine-l0-carboxylate on the spatial memory retention of ten aged-impaired (AI) rats in the RAM test, where the vehicle control was tested 3 times, and the different doses of ethyl 3-methoxy-7-methyl-9H- benzo[f]imidazo[l,5-a][l,2,4]triazolo[4,3-d][l,4]diazepine-l0-carboxylate were tested twice;
• black bars refer to rats treated with vehicle alone and open bars refer to rats treated with ethyl 3-methoxy-7-methyl-9H-benzo[f]imidazo[l,5-a][l,2,4]triazolo[4,3- d][l,4]diazepine-l0-
• Figure 6 is a graph showing the effect of ethyl 3-methoxy-7-methyl-9H- benzo[f]imidazo[l,5-a][l,2,4]triazolo[4,3-d][l,4]diazepine-l0-carboxylate (administered intravenously) on the binding of Rol545 l3 in the hippocampus and cerebellum.
• Figure 7 is a graph showing dose-dependent GABAA a5 receptor occupancy by ethyl 3-methoxy-7-methyl-9H-benzo[f]imidazo[l,5-a][l,2,4]triazolo[4,3- d][l,4]diazepine-l0-carboxylate administered intravenously, as calculated by the ratio between hippocampus (a region of high GABAACX5 receptor density) exposure of RO 15- 4513 and cerebellum (a region with low GABA ACX 5 receptor density) exposure of RO 15- 4513 to define full occupancy.
• Figure 8(A)-(C) are graphs showing the effect of 6,6 dimethyl-3 -(3- hydroxypropyl)thio-l-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one, as compared to vehicle dimethyl sulfoxide (DMSO), in aged-impaired rats using a Morris water maze behavioral task.
• DMSO vehicle dimethyl sulfoxide
• Figure 8(A) shows the escape latency (i.e., the average time in seconds rats took to find the hidden platform in the water pool) during training in rats received 6,6 dimethyl-3-(3-hydroxypropyl)thio-l-(thiazol-2-yl)-6,7-dihydro-2- benzothiophen-4(5H)-one and rats received vehicle DMSO;
• Figure 8(B) shows the amount of time spent in target annulus and opposite annulus by rats received 6,6 dimethyl-3-(3-hydroxypropyl)thio-l-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)- one and rats received vehicle DMSO;
• Figure 8(C) shows number of crossing in target annulus and opposite annulus by rats received 6,6 dimethyl-3 -(3 -hydroxypropyl)thio- 1- (thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one and rats received
• neurobiology neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry, described herein, are those well known and commonly used in the art.
• agent is used herein to denote a chemical compound (such as an organic or inorganic compound (including, such as, a compound of the present invention), a mixture of chemical compounds), a biological macromolecule (such as a nucleic acid, an antibody, including parts thereof as well as humanized, chimeric and human antibodies and monoclonal antibodies, a protein or portion thereof, e.g ., a peptide, a lipid, a carbohydrate), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues.
• Agents include, for example, agents which are known with respect to structure, and those which are not known with respect to structure.
• the a5-containing GABA A receptor agonist activity of such agents may render them suitable as“therapeutic agents” in the methods and compositions of this invention.
• A“patient,”“subject,” or“individual” are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (including bovine, porcine, etc.), companion animals (e.g ., canine, feline, etc.) and rodents (e.g., mice and rats).
• “Cognitive function” or“cognitive status” refers to any higher order intellectual brain process or brain state, respectively, involved in learning and/or memory including, but not limited to, attention, information acquisition, information processing, working memory, short-term memory, long-term memory, anterograde memory, retrograde memory, memory retrieval, discrimination learning, decision-making, inhibitory response control, attentional set-shifting, delayed reinforcement learning, reversal learning, the temporal integration of voluntary behavior, expressing an interest in one’s surroundings and self-care, speed of processing, reasoning and problem solving and social cognition.
• cognitive function may be measured, for example and without limitation, by the clinical global impression of change scale (CIBIC-plus scale); the Mini Mental State Exam (MMSE); the Neuropsychiatric Inventory (NPI); the Clinical
• CDR Dementia Rating Scale
• CANTAB Cambridge Neuropsychological Test Automated Battery
• SCAG Sandoz Clinical Assessment-Geriatric
• SCAG Buschke Selective Reminding Test
• WMS-R Wechsler Memory Scale-Revised
• Benton Visual Retention Test or the explicit 3-alternative forced choice task, or MATRICS consensus neuropsychological test battery.
• cognitive function may be measured in various conventional ways known in the art, including using a Morris Water Maze (MWM), Barnes circular maze, elevated radial arm maze, T maze or any other mazes in which the animals use spatial information.
• MMM Morris Water Maze
• Cognitive function can be assessed by reversal learning, extradimensional set shifting, conditional discrimination learning and assessments of reward expectancy.
• Other tests known in the art may also be used to assess cognitive function, such as novel object recognition and odor recognition tasks.
• Cognitive function may also be measured using imaging techniques such as Positron Emission Tomography (PET), functional magnetic resonance imaging (fMRI), Single Photon Emission Computed Tomography (SPECT), or any other imaging technique that allows one to measure brain function.
• imaging techniques such as Positron Emission Tomography (PET), functional magnetic resonance imaging (fMRI), Single Photon Emission Computed Tomography (SPECT), or any other imaging technique that allows one to measure brain function.
• cognitive function may also be measured with electrophysiological techniques.
• “Promoting” cognitive function refers to affecting impaired cognitive function so that it more closely resembles the function of a normal, unimpaired subject.
• Cognitive function may be promoted to any detectable degree, but in humans preferably is promoted sufficiently to allow an impaired subject to carry out daily activities of normal life at a level of proficiency as close as possible to a normal, unimpaired subject or an age- matched normal, unimpaired subject.
• “promoting” cognitive function in a subject affected by age- related cognitive refers to affecting impaired cognitive function so that it more closely resembles the function of an aged-matched normal, unimpaired subject, or the function of a young adult subject.
• Cognitive function of that subject may be promoted to any detectable degree, but in humans preferably is promoted sufficiently to allow an impaired subject to carry out daily activities of normal life at a level of proficiency close as possible to a normal, unimpaired subject or a young adult subject or an age-matched normal unimpaired subj ect.
• Preserving cognitive function refers to affecting normal or impaired cognitive function such that it does not decline or does not fall below that observed in the subject upon first presentation or diagnosis, or delays such decline.
• “Improving” cognitive function includes promoting cognitive function and/or preserving cognitive function in a subject.
• Cognitive impairment refers to cognitive function in subjects that is not as robust as that expected in a normal, unimpaired subject. In some cases, cognitive function is reduced by about 5%, about 10%, about 30%, or more, compared to cognitive function expected in a normal, unimpaired subject. In some cases,“cognitive impairment” in subjects affected by aged-related cognitive impairment refers to cognitive function in subjects that is not as robust as that expected in an aged-matched normal, unimpaired subject, or the function of a young adult subject (i.e. subjects with mean scores for a given age in a cognitive test).
• Age-related cognitive impairment refers to cognitive impairment in aged subjects, wherein their cognitive function is not as robust as that expected in an age- matched normal subject or as that expected in young adult subjects. In some cases, cognitive function is reduced by about 5%, about 10%, about 30%, or more, compared to cognitive function expected in an age-matched normal subject. In some cases, cognitive function is as expected in an age-matched normal subject, but reduced by about 5%, about 10%, about 30%, about 50% or more, compared to cognitive function expected in a young adult subject.
• Age-related impaired cognitive function may be associated with Mild Cognitive Impairment (MCI) (including amnestic MCI and non-amnestic MCI), Age-Associated Memory Impairment (AAMI), and Age-related Cognitive Decline (ARCD).
• MCI Mild Cognitive Impairment
• AAMI Age-Associated Memory Impairment
• ARCD Age-related Cognitive Decline
• Cognitive impairment associated with AD or related to AD or in AD refers to cognitive function in subjects that is not as robust as that expected in subjects who have not been diagnosed AD using conventional methodologies and standards.
• MCI Mild Cognitive Impairment
• memory complaint as reported by patient, informant, or physician
• ADLs normal activities of daily living
• normal global cognitive function (4) abnormal memory for age (defined as scoring more than 1.5 standard deviations below the mean for a given age), and (5) absence of indicators of dementia (as defined by DSM-IV guidelines).
• the cognitive deficit in subjects with MCI may involve any cognition area or mental process including memory, language, association, attention, perception, problem solving, executive function and visuospatial skills. See , e.g. ,
• MCI is further subdivided into amnestic MCI (aMCI) and non-amnestic MCI, characterized by the impairment (or lack thereof) of memory in particular.
• aMCI amnestic MCI
• MCI is defined as aMCI if memory is found to be impaired given the age and education level of the subject.
• MCI is defines an non-amnestic MCI.
• aMCI and non-amnestic MCI can both be further subdivided into single or multiple domain MCI.
• aMCI-single domain refers to a condition where memory, but not other cognitive areas are impaired.
• aMCI-multiple domain refers to a condition where memory and at least one other cognitive area are impaired.
• Non-amnestic MCI is single domain or multiple domain dependent on whether nor not more than one non-memory cognitive area is impaired. See , e.g, Peterson and Negash, CNS Spectr. 13 :45-53, 2008.
• Diagnosis of MCI usually entails an objective assessment of cognitive impairment, which can be garnered through the use of well-established
• MMSE Mini Mental State Examination
• CANTAB Cambridge Neuropsychological Test Automated Battery
• AVLT Rey Auditory Verbal Learning Test
• WMS-R Logical Memory Subtest of the revised Wechsler Memory Scale
• NYU New York LTniversity
• AAMI Align-Associate Memory Impairment
• a patient may be considered to have AAMI if he or she is at least 50 years old and meets all of the following criteria: a) The patient has noticed a decline in memory performance, b) The patient performs worse on a standard test of memory compared to young adults, c) All other obvious causes of memory decline, except normal aging, have been ruled out (in other words, the memory decline cannot be attributed to other causes such as a recent heart attack or head injury, depression, adverse reactions to medication, Alzheimer's disease, etc.).
• Age-Related Cognitive Decline refers to declines in memory and cognitive abilities that are a normal consequence of aging in humans (e.g ., Craik & Salthouse, 1992). This is also true in virtually all mammalian species.
• Age-Associated Memory Impairment refers to older persons with objective memory declines relative to their younger years, but cognitive functioning that is normal relative to their age peers (Crook et ah, 1986).
• Age-Consistent Memory Decline is a less pejorative label which emphasizes that these are normal developmental changes (Crook, 1993; Larrabee, 1996), are not pathophysiological (Smith et ah, 1991), and rarely progress to overt dementia (Youngjohn & Crook, 1993).
• the DSM-IV (1994) has codified the diagnostic classification of ARCD.
• “Dementia” refers to a condition characterized by severe cognitive deficit that interferes in normal activities of daily living. Subjects with dementia also display other symptoms such as impaired judgment, changes in personality, disorientation, confusion, behavior changes, trouble speaking, and motor deficits. There are different types of dementias, such as Alzheimer’s disease (AD), vascular dementia, dementia with Lewy bodies, and frontotemporal dementia.
• AD Alzheimer’s disease
• vascular dementia dementia with Lewy bodies
• frontotemporal dementia frontotemporal dementia.
• AD Alzheimer’s disease
• memory deficits in its early phase Later symptoms include impaired judgment, disorientation, confusion, behavior changes, trouble speaking, and motor deficits.
• Histologically, AD is characterized by beta-amyloid plaques and tangles of protein tau.
• Vascular dementia is caused by strokes. Symptoms overlap with those of AD, but without the focus on memory impairment.
• Dementia with Lewy bodies is characterized by abnormal deposits of alpha- synuclein that form inside neurons in the brain.
• Cognitive impairment may be similar to AD, including impairments in memory and judgment and behavior changes.
• Frontotemporal dementia is characterized by gliosis, neuronal loss, superficial spongiform degeneration in the frontal cortex and/or anterior temporal lobes, and Picks’ bodies. Symptoms include changes in personality and behavior, including a decline in social skills and language expression/comprehension.
• PTSD Post traumatic stress disorder
• PTSD characterized by an immediate or delayed response to a catastrophic event, characterized by re-experiencing the trauma, psychic numbing or avoidance of stimuli associated with the trauma, and increased arousal.
• Re-experiencing phenomena include intrusive memories, flashbacks, nightmares, and psychological or physiological distress in response to trauma reminders.
• Such responses produce anxiety and can have significant impact, both chronic and acute, on a patient’s quality of life and physical and emotional health.
• PTSD is also associated with impaired cognitive performance, and older individuals with PTSD have greater decline in cognitive performance relative to control patients.
• “Schizophrenia” refers to a chronic debilitating disorder, characterized by a spectrum of psychopathology, including positive symptoms such as aberrant or distorted mental representations (e.g ., hallucinations, delusions), negative symptoms characterized by diminution of motivation and adaptive goal-directed action (e.g., anhedonia, affective flattening, avolition), and cognitive impairment. While abnormalities in the brain are proposed to underlie the full spectrum of psychopathology in schizophrenia, currently available antipsychotics are largely ineffective in treating cognitive impairments in patients.
• BP Bipolar disorder
• manic depressive disorder or “manic depressive illness” refers to a chronic psychological/mood disorder which can be characterized by significant mood changes including periods of depression and euphoric manic periods.
• BP may be diagnosed by a skilled physician based on personal and medical history, interview consultation and physical examinations.
• mania or “manic periods” or other variants refers to periods where an individual exhibits some or all of the following characteristics: racing thoughts, rapid speech, elevated levels of activity and agitation as well as an inflated sense of self-esteem, euphoria, poor judgment, insomnia, impaired concentration and aggression.
• ALS Amyotrophic lateral sclerosis
• ALS refers to a progressive, fatal, neurodegenerative disease characterized by a degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.
• ALS is also characterized by neuronal degeneration in the entorhinal cortex and hippocampus, memory deficits, and neuronal hyperexcitability in different brain areas such as the cortex.
• Cancer-therapy-related cognitive impairment refers to cognitive impairment that develops in subjects that are treated with cancer therapies such as chemotherapy (e.g., chemobrain) and radiation. Cytotoxicity and other adverse side-effects on the brain of cancer therapies result in cognitive impairment in such functions as memory, learning and attention.
• cancer therapies such as chemotherapy (e.g., chemobrain) and radiation. Cytotoxicity and other adverse side-effects on the brain of cancer therapies result in cognitive impairment in such functions as memory, learning and attention.
• Parkinson’s disease is a neurological disorder characterized by a decrease of voluntary movements.
• the afflicted patient has reduction of motor activity and slower voluntary movements compared to the normal individual.
• the patient has characteristic "mask” face, a tendency to hurry while walking, bent over posture and generalized weakness of the muscles.
• Another important feature of the disease is the tremor of the extremities occurring at rest and decreasing during movements.
• “Autism,” as used herein, refers to an autism spectrum disorder characterized by a neural development disorder leading to impaired social interaction and communication by restricted and repetitive behavior.
• “Autism Spectrum Disorder” refers to a group of developmental disabilities that includes: autism; Asperger syndrome; pervasive developmental disorder not otherwise specified (PDD-NOS or atypical autism); Rett syndrome; and childhood disintegrative disorder.
• mental retardation includes, but are not limited to, Down syndrome, velocariofacial syndrome, fetal alcohol syndrome, Fragile X syndrome, Klinefelter’s syndrome, neurofibromatosis, congenital hypothyroidism, Williams syndrome, phenylketonuria (PKU), Smith-Lemli-Opitz syndrome, Prader-Willi syndrome, Phelan-McDermid syndrome, Mowat-Wilson syndrome, ciliopathy, Lowe syndrome and siderium type X-linked mental retardation.
• Down syndrome is a disorder that includes a combination of birth defects, including some degree of mental retardation, characteristic facial features and, often, heart defects, increased infections, problems with vision and hearing, and other health problems.
• Fragile X syndrome is a prevalent form of inherited mental retardation, occurring with a frequency of 1 in 4,000 males and 1 in 8,000 females. The syndrome is also characterized by developmental delay,
• Obsessive compulsive disorder is a mental condition that is most commonly characterized by intrusive, repetitive unwanted thoughts (obsessions) resulting in compulsive behaviors and mental acts that an individual feels driven to perform (compulsion).
• OCD Obsessive compulsive disorder
• Current epidemiological data indicates that OCD is the fourth most common mental disorder in the United States.
• Substance addiction e.g ., drug addiction, alcohol addiction
• the addiction is not triggered instantaneously upon exposure to substance of abuse. Rather, it involves multiple, complex neural adaptations that develop with different time courses ranging from hours to days to months (Kauer J. A. Nat. Rev.
• the path to addiction generally begins with the voluntary use of one or more controlled substances, such as narcotics, barbiturates,
• methamphetamines methamphetamines, alcohol, nicotine, and any of a variety of other such controlled substances.
• substance addiction generally is characterized by compulsive substance craving, seeking and use that persist even in the face of negative consequences.
• the cravings may represent changes in the underlying neurobiology of the patient which likely must be addressed in a meaningful way if recovery is to be obtained.
• Substance addiction is also characterized in many cases by withdrawal symptoms, which for some substances are life threatening (e.g ., alcohol, barbiturates) and in others can result in substantial morbidity (which may include nausea, vomiting, fever, dizziness, and profuse sweating), distress, and decreased ability to obtain recovery.
• alcoholism also known as alcohol dependence
• Alcoholism is primarily characterized by four symptoms, which include cravings, loss of control, physical dependence and tolerance. These symptoms also may characterize addictions to other controlled substances. The craving for alcohol, as well as other controlled substances, often is as strong as the need for food or water. Thus, an alcoholic may continue to drink despite serious family, health and/or legal ramifications.
• Treating” a condition or patient refers to taking steps to obtain beneficial or desired results, including clinical results.
• Beneficial or desired clinical results include, but are not limited to, preventing or slowing the progression of the disease or disorder, or alleviation, amelioration, or slowing the progression, of one or more symptoms of cognitive impairment associated with CNS disorders, such as age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer’s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy- related cognitive impairment, mental retardation, Parkinson’s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.
• MCI Mild Cognitive Impairment
• aMCI amnestic MCI
• AAMI Age- Associated Memory Impairment
• ARCD
• treatment comprises preventing or slowing the progression, of a CNS disorder (such as one as described herein).
• treatment comprises alleviation, amelioration, or slowing the progression of one or more symptoms associated with that CNS disorder.
• the symptom to be treated is cognitive impairment or cognitive deficit. Treating age-related cognitive impairment further comprises slowing the conversion of age-related cognitive impairment (including, but not limited to MCI, ARCD and AAMI) into dementia (e.g., AD).
• Treating cognitive impairment refers to taking steps to improve cognitive function in a subject with cognitive impairment so that the subject’s performance in one or more cognitive tests is improved to any detectable degree, or is prevented from further decline.
• that subject’s cognitive function, after treatment of cognitive impairment more closely resembles the function of a normal, unimpaired subject.
• Treatment of cognitive impairment in humans may improve cognitive function to any detectable degree, but is preferably improved sufficiently to allow the impaired subject to carry out daily activities of normal life at the same level of proficiency as a normal, unimpaired subject.
• “treating cognitive impairment” refers to taking steps to improve cognitive function in a subject with cognitive impairment so that the subject’s performance in one or more cognitive tests is improved to any detectable degree, or is prevented from further decline.
• that subject’s cognitive function, after treatment of cognitive impairment more closely resembles the function of a normal, unimpaired subject.
• “treating cognitive impairment” in a subject affecting by age-related cognitive impairment refers to takings steps to improve cognitive function in the subject so that the subject’s cognitive function, after treatment of cognitive impairment, more closely resembles the function of an age-matched normal, unimpaired subject, or the function of a young adult subject.
• administering or "administration of a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art.
• a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally,
• a compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g. , patches and pumps, or formulations, which provide for the extended, slow, or controlled release of the compound or agent.
• Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
• the administration includes both direct administration, including self-administration, and indirect administration, including the act of prescribing a drug.
• a physician who instructs a patient to self-administer a drug, or to have the drug administered by another and/or who provides a patient with a prescription for a drug is administering the drug to the patient.
• Appropriate methods of administering a substance, a compound or an agent to a subject will also depend, for example, on the age of the subject, whether the subject is active or inactive at the time of administering, whether the subject is cognitively impaired at the time of administering, the extent of the impairment, and the chemical and biological properties of the compound or agent (e.g . solubility, digestibility, bioavailability, stability and toxicity).
• a compound or an agent is administered orally, e.g., to a subject by ingestion, or intravenously, e.g, to a subject by injection.
• the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.
• a“a5-containing GABAA receptor agonist,”“a5 -containing GABAA R agonist” or a“GABAA a5 receptor agonist” and other variations as used herein refer to a compound that enhances the function of a5-containing GABAA receptor (GABAA R), i.e., a compound that increase GABA-gated Cl currents.
• GABAA R a5-containing GABAA R agonist as used herein refers to a positive allosteric modulator, which potentiates the activity of GABA.
• a5-containing GABAA receptor agonists suitable for use in the present invention, include the a5-containing GABAA receptor agonists of all formulas and specific a5-containing GABAA receptor agonists described herein, and their hydrates, solvates, polymorphs, salts (e.g, pharmaceutically acceptable salts), isomers (e.g, stereoisomers, E/Z isomers, and tautomers), and combinations thereof.
• Antipsychotic refers to (1) a typical or an atypical antipsychotic; (2) an agent that is selected from dopaminergic agents, glutamatergic agents, NMDA receptor positive allosteric modulators, glycine reuptake inhibitors, glutamate reuptake inhibitor, metabotropic glutamate receptors (mGluRs) agonists or positive allosteric modulators (PAMs) (e.g, mGluR2/3 agonists or PAMs), glutamate receptor glur5 positive allosteric modulators (PAMs), Ml muscarinic acetylcholine receptor (mAChR) positive allosteric modulators (PAMs), histamine H3 receptor antagonists, AMP A/kainate receptor antagonists, ampakines (CX-516), glutathione prodrugs, noradrenergic agents, serotonin receptor modulators, cholinergic agents, can
• PAMs PAMs
• serotonin 2C agonists an agent that is useful in treating one or more signs or symptoms of schizophrenia or bipolar disorder (in particular, mania).
• Typical antipsychotics refer to conventional antipsychotics, which produce antipsychotic effects as well as movement related adverse effects related to disturbances in the nigrostriatal dopamine system.
• extrapyramidal side effects include Parkinsonism, akathisia, tardive dyskinesia and dystonia. See Baldessarini and Tarazi in Goodman & Gilman's The Pharmacological Basis of Therapeutics 10 Edition, 2001, pp. 485-520.
• Atypical antipsychotics refer to antipsychotic drugs that produce antipsychotic effects with little or no EPS and include, but are not limited to, aripiprazole, asenapine, clozapine, iloperidone, olanzapine, lurasidone, paliperidone, quetiapine, risperidone and ziprasidone. "Atypical" antipsychotics differ from
• conventional antipsychotics in their pharmacological profiles. While conventional antipsychotics are characterized principally by D 2 dopamine receptor blockade, atypical antipsychotics show antagonist effects on multiple receptors including the 5HT a and 5HT C serotonin receptors and varying degrees of receptor affinities. Atypical antipsychotic drugs are commonly referred to as serotonin/dopamine antagonists, reflecting the influential hypothesis that greater affinity for the 5HT 2 receptor than for the D 2 receptor underlies "atypical" antipsychotic drug action or "second generation” antipsychotic drugs.
• the atypical antipsychotics often display side effects, including, but not limited to, weight gain, diabetes (e.g ., type II diabetes mellitus), hyperlipidemia, QTc interval prolongation, myocarditis, sexual side effects, extrapyramidal side effects and cataract.
• side effects including, but not limited to, weight gain, diabetes (e.g ., type II diabetes mellitus), hyperlipidemia, QTc interval prolongation, myocarditis, sexual side effects, extrapyramidal side effects and cataract.
• side effects including, but not limited to, weight gain, diabetes (e.g ., type II diabetes mellitus), hyperlipidemia, QTc interval prolongation, myocarditis, sexual side effects, extrapyramidal side effects and cataract.
• atypical antipsychotics do not represent a homogeneous class, given their differences in the context of both alleviation of clinical symptoms and their potential for inducing side effects such as the ones listed above.
• Memantine is chemically known as 3,5-dimethyladamantan-l-amine or 3,5- dimethyltricyclo[3.3. l . l 3,7 ]decan-l-amine, which is an uncompetitive N-methyl-D- aspartate (NMD A) receptor antagonist with moderate affinity.
• NMD A N-methyl-D- aspartate
• the proprietary names for memantine include: Axura® and Akatinol® (Merz), Namenda® (Forest Laboratories), Ebixa® and Abixa® (Lundbeck), and Memox® (Unipharm).
• Memantine is approved for the treatment of moderate to severe Alzheimer's disease (AD) in the United States at a dose of up to 28 mg/day. Derivatives or analogs of memantine, which include
• Memantine as used in the present invention, includes memantine and its derivatives and analogs, as well as hydrates, polymorphs, prodrugs, salts, and solvates thereof.
• Memantine as used herein, also includes a composition comprising memantine or a derivative or an analog or a pharmaceutically acceptable salt, hydrate, solvate,
• composition optionally further comprises at least one additional therapeutic agent (such as a therapeutic agent useful for treating a
• the memantine composition suitable for use in the present invention comprises memantine and a second therapeutic agent that is donepezil (under the trade name Aricept).
• Acetylcholinesterase inhibitor or“AChE-I” as used herein refers to an agent that inhibits the ability of the cholinesterase enzyme to break down the neurotransmitter acetylcholine, thereby increasing the concentration and duration of acetylcholine, mainly in brain synapses or neuromuscular junctions. AChE-Is suitable for use in this
• application may include, for example, the subcategories of (i) reversible non-competitive inhibitors or reversible competitive inhibitors, (ii) irreversible, and (iii) quasi-irreversible inhibitors.
• a5-containing GABAA receptor agonist e.g, a a5-containing GABAA receptor positive allosteric modulator
• a second therapeutic agent e.g, an antipsychotic, memantine or an AChE-I
• a time separation of no more than about 15 minutes, and in some embodiments no more than about 10 minutes.
• the a5-containing GABAA receptor agonist e.g, an a5-containing GABAA receptor positive allosteric modulator
• a second therapeutic agent e.g, an antipsychotic, memantine or an AChE-I
• their salts, hydrates, solvates, or polymorphs may be contained in the same dosage (e.g, a unit dosage form comprising both the a5-containing GABAA receptor agonist (e.g, an a5- containing GABAA receptor positive allosteric modulator) and a second therapeutic agent (e.g, an antipsychotic, memantine or an AChE-I) or in discrete dosages (e.g, the a5- containing GABAA receptor agonist (e.g, an a5-containing GABAA receptor positive allosteric modulator) or its salt, hydrate, solvate, or polymorph is contained in one dosage form and a second therapeutic agent (e.g, an antipsychotic, memantine or an AChE-
• a5- containing GABAA receptor agonist e.g, a a5-containing GABAA receptor positive allosteric modulator
• a second therapeutic agent e.g, an antipsychotic, memantine or an AChE-I
• salts, hydrates, solvates, polymorphs are administered with a time separation of more than about 15 minutes, and in some embodiments more than about one hour, or up to 12-24 hours.
• Either the a5-containing GABAA receptor agonist (e.g, a a5-containing GABAA receptor positive allosteric modulator) or a second therapeutic agent (e.g, an antipsychotic, memantine or an AChE- I) may be administered first.
• the a5-containing GABAA receptor agonist (e.g, a a5- containing GABAA receptor positive allosteric modulator) and a second therapeutic agent (e.g, an antipsychotic, memantine or an AChE-I), or their salts, hydrates, solvents, or polymorphs, for sequential administration may be contained in discrete dosage forms, optionally contained in the same container or package.
• a "therapeutically effective amount" of a drug or agent is an amount of a drug or an agent that, when administered to a subject will have the intended therapeutic effect, e.g. improving cognitive function in a subject, e.g, a patient having cognitive impairment associated with a CNS disorder.
• the full therapeutic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses.
• a therapeutically effective amount may be administered in one or more
• CNS disorders such as age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer’s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia , bipolar, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson’s disease
• PD autism spectrum disorders
• fragile X disorder fragile X disorder
• Rett syndrome compulsive behavior
• substance addiction substance addiction
• the compounds of the present invention also include prodrugs, analogs or derivatives.
• prodrug is art-recognized and is intended to encompass
• a common method for making a prodrug is to select moieties which are hydrolyzed or metabolized under physiological conditions to provide the desired compound or agent.
• the prodrug is converted by an enzymatic activity of the host animal to a GABAA a5 receptor positive allosteric modulator.
• Analog is used herein to refer to a compound which functionally resembles another chemical entity, but does not share the identical chemical structure.
• an analog is sufficiently similar to a base or parent compound such that it can substitute for the base compound in therapeutic applications, despite minor structural differences.
• aliphatic refers to a straight chained or branched alkyl, alkenyl or alkynyl. It is understood that alkenyl or alkynyl embodiments need at least two carbon atoms in the aliphatic chain. Aliphatic groups typically contain from 1 (or 2) to 12 carbons, such as from 1 (or 2) to 4 carbons.
• aryl refers to a monocyclic or bicyclic carbocyclic aromatic ring system.
• Aryl as used herein includes a (C6-Cl2)-aryl-.
• aryl as used herein can be a C6-C10 monocyclic or C8-C12 bicyclic carbocyclic aromatic ring system.
• aryl as used herein can be a (C6-Cl0)-aryl-.
• Phenyl (or Ph) is an example of a monocyclic aromatic ring system.
• Bicyclic aromatic ring systems include systems wherein both rings are aromatic, e.g ., naphthyl, and systems wherein only one of the two rings is aromatic, e.g. , tetralin.
• heterocyclic refers to a monocyclic or bicyclic non aromatic ring system having 1 to 4 heteroatom or heteroatom groups selected from O, N, NH, S, SO, or S0 2 in a chemically stable arrangement.
• Heterocyclic as used herein includes a 3- to 12- membered heterocyclyl- having 1-4 heteroatoms independently selected from O, N, NH, S, SO, or SO2 .
• heterocyclic as used herein can be a 3- to 10- membered monocyclic or 8- to 12- membered bicyclic non-aromatic ring system having 1 to 4 heteroatom or heteroatom groups selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement.
• heterocyclic as used herein can be a 3- to 10- membered heterocyclyl- having 1-4 heteroatoms independently selected from O, N, NH, S, SO, or SO2 .
• a bicyclic non-aromatic ring system embodiment of "heterocyclyl” one or both rings may contain said heteroatom or heteroatom groups.
• one of the two rings may be aromatic.
• a non-aromatic heterocyclic ring may optionally be fused to an aromatic carbocycle.
• heterocyclic rings include 3-lH-benzimidazol-2-one, 3-(l-alkyl)- benzimidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3- tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3- thiomorpholino, 4-thiomorpholino, l-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1- tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, l-piperidinyl, 2- piperidinyl, 3-piperidinyl, l-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1- piperidinyl, 2-piperid
• heteroaryl refers to a monocyclic or bicyclic aromatic ring system having 1 to 4 heteroatom or heteroatom groups selected from O, N, NH or S in a chemically stable arrangement.
• Heteroaryl as used herein includes a 5- to 12- membered heteroaryl having 1-4 heteroatoms independently selected from O, N, NH or S.
• heteroaryl as used herein can be a 5- to 10- membered heteroaryl having 1-4 heteroatoms independently selected from O, N, NH or S.
• heteroaryl as used herein can be a 5- to 10- membered monocyclic or 8- to 12- membered bicyclic aromatic ring system having 1 to 4 heteroatom or heteroatom groups selected from O, N, NH or S in one or both rings in a chemically stable arrangement.
• heteroaryl a bicyclic aromatic ring system embodiment of "heteroaryl”:
• - one or both rings may contain said heteroatom or heteroatom groups.
• heteroaryl rings examples include 2-furanyl, 3-furanyl, N-imidazolyl, 2- imidazolyl, 4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5- isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2- pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g, 3 -pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g. , 5-tetrazolyl), triazolyl (e.g, 2-triazolyl and 5-triazolyl), 2-thienyl
• quinolinyl e.g, 2-quinolinyl, 3 -quinolinyl, 4-quinolinyl
• isoquinolinyl e.g, l-isoquinolinyl, 3- isoquinolinyl, or 4-isoquinolinyl.
• cycloalkyl or cycloalkenyl refers to a monocyclic or fused or bridged bicyclic carbocyclic ring system that is not aromatic.
• cycloalkyl or cycloalkenyl as used herein can be a C3-C10 monocyclic or fused or bridged C8-C12 bicyclic carbocyclic ring system that is not aromatic.
• Cycloalkenyl rings have one or more units of unsaturation.
• Preferred cycloalkyl or cycloalkenyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl,
• heteroarylkyl refers to an alkyl in which a heteroaryl group is substituted for an alkyl H atom.
• the alkyl group is any straight chain hydrocarbon, and can include from 1 to 12 carbon atoms (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl), wherein said alkyl group can be substituted with any heteroaryl group, including but not limited to, 2- furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5- oxazolyl, N-pyrrol
• a substituted moiety is described without indicating the atom via which such moiety is bonded to a substituent, then the substituent may be bonded via any appropriate atom in such moiety.
• a substituent on the heteroaryl can be bonded to any of the ring-forming atoms of the heteroaryl ring that are substitutable (i.e., atoms bound to one or more hydrogen atoms).
• the pyridine ring may be bound to the benzodiazepine derivative through any one of the ring carbon atoms in the pyridine ring.
• a R group is defmied as a pyrazole, and
• the pyrazole ring may be bound to the benzodiazepine derivative through any one of the ring carbon atoms of the pyrazole ring, or to the sp 3 N-atom.
• the carbon atom designations may have the indicated integer and any intervening integer.
• the number of carbon atoms in a (Cl-C4)-alkyl group is 1, 2, 3, or 4. It should be understood that these designations refer to the total number of atoms in the appropriate group.
• the total number of carbon atoms and heteroatoms is 3 (as in aziridine), 4, 5, 6 (as in morpholine), 7, 8, 9, or 10.
• “Pharmaceutically acceptable salt” is used herein to refer to an agent or a compound according to the invention that is a therapeutically active, non-toxic base and acid salt form of the compounds.
• the acid addition salt form of a compound that occurs in its free form as a base can be obtained by treating said free base form with an appropriate acid such as an inorganic acid, for example, a hydrohalic such as hydrochloric or hydrobromic, sulfuric, nitric, phosphoric and the like; or an organic acid, such as, for example, acetic, hydroxy acetic, propanoic, lactic, pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p- toluenesulfonic, cyclic, salicylic, p- aminosalicylic, pamoic and the like. See, e.g ., a
• base addition salt form e. g. metal or amine salts
• Appropriate base salt forms include, for example, ammonium salts, alkali and earth alkaline metal salts, e. g., lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e. g. N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
• said salt forms can be converted into the free forms by treatment with an appropriate base or acid.
• solvates include for example hydrates, alcoholates and the like. See, e.g., WO 01/062726.
• hydrate refers to a combination of water with a compound wherein the water retains its molecular state as water and is either absorbed, adsorbed or contained within a crystal lattice of the substrate compound.
• polymorph refers to different crystalline forms of the same compound and other solid state molecular forms including pseudo-polymorphs, such as hydrates (e.g, bound water present in the crystalline structure) and solvates (e.g, bound solvents other than water) of the same compound.
• pseudo-polymorphs such as hydrates (e.g, bound water present in the crystalline structure) and solvates (e.g, bound solvents other than water) of the same compound.
• pseudo-polymorphs such as hydrates (e.g, bound water present in the crystalline structure) and solvates (e.g, bound solvents other than water) of the same compound.
• pseudo-polymorphs such as hydrates (e.g, bound water present in the crystalline structure) and solvates (e.g, bound solvents other than water) of the same compound.
• Different crystalline polymorphs have different crystal structures due to a different packing of the molecules in the lattice. This results in a different crystal symmetry and/or unit
• Crystalline polymorphic forms are of interest to the pharmaceutical industry and especially to those involved in the development of suitable dosage forms. If the polymorphic form is not held constant during clinical or stability studies, the exact dosage form used or studied may not be comparable from one lot to another. It is also desirable to have processes for producing a compound with the selected polymorphic form in high purity when the compound is used in clinical studies or commercial products since Impurities present may produce undesired toxicological effects. Certain polymorphic forms may exhibit enhanced thermodynamic stability or may be more readily manufactured in high purity in large quantities, and thus are more suitable for inclusion in pharmaceutical formulations.
• Certain polymorphs may display other advantageous physical properties such as lack of hygroscopic tendencies, improved solubility, and enhanced rates of dissolution due to different lattice energies.
• This application contemplates all the isomers of the compounds of formulae I-XI “Isomer” as used herein includes optical isomers (such as stereoisomers, e.g ., enantiomers and diastereoisomers), Z (zusammen) or E (entussi) isomers, and tautomers.
• optical isomers such as stereoisomers, e.g ., enantiomers and diastereoisomers
• Z zusammen
• E entodor
• tautomers e.g., enantiomers and diastereoisomers
• Many of the compounds useful in the methods and compositions of this invention have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30.
• the invention also relates to all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g. , WO 01/062726. Furthermore, certain compounds which contain alkenyl groups may exist as Z
• the compounds of the invention enhance the function of a5-containing GABAA R, i.e., they are a5-containing GABAA R agonists (e.g, a5-containing GABAA receptor positive allosteric modulators) and are capable of increasing GABA-gated CT currents.
• a5-containing GABAA R agonists e.g, a5-containing GABAA receptor positive allosteric modulators
• the invention further provides pharmaceutical compositions comprising one or more compounds of the invention together with a pharmaceutically acceptable carrier or excipient.
• the pharmaceutical compositions of this application may further comprise a second therapeutic agent, such as an antipsychotic, memantine or an AChE-I.
• the invention further provides methods for treating cognitive impairment associated with said CNS disorders that are responsive to positive allosteric modulators of a5-containing GABAA receptor, e.g, age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment
• aMCI Mild Cognitive Impairment
• aMCI amnestic MCI
• the method is a method of treating the age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment
• treatment comprises preventing or slowing the progression of a CNS disorder as described herein (such as those described herein).
• treatment comprises alleviation, amelioration, or slowing the progression of one or more symptoms associated with the CNS disorder.
• the symptom to be treated is cognitive impairment or cognitive deficit.
• a method of preserving or improving cognitive function in a subject in need thereof comprising the step of administering to said subject a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt, hydrate, solvate, polymorph, isomer, or combination thereof.
• the various CNS disorders with cognitive impairment may have a variety of etiologies.
• age-related cognitive impairment Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer’s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy- related cognitive impairment, mental retardation, Parkinson’s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome,, compulsive behavior, and substance addiction
• MCI Mild Cognitive Impairment
• aMCI amnestic MCI
• AAMI Age- Associated Memory Impairment
• ARCD Age Related Cognitive Decline
• AD Alzheimer’s Disease(AD)
• prodromal AD post traumatic stress disorder
• PTSD post traumatic stress disorder
• ALS amyotrophic lateral sclerosis
• PD cognitive impairment
• autism spectrum disorders
• A is C, CR 6 , or N;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
• D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• n R 2 is independently substituted with 0-5 R’;
• n and n are independently integers selected from 0-4;
• p is an integer selected from 2-4;
• each occurrence of the bond“ ” is either a single bond or a double bond
• R 1 , R 2 , R 4 , and R 5 are each independently selected from:
• R 3 is absent or is selected from: halogen, -R, -OR, -N0 2 , -NCS, -CN, -CF 3 , -OCF 3 , -S1R3, -N(R) 2 , -SR, -SOR,
• each R 6 is independently -H or -(Cl-C6)alkyl
• each R 7 is independently -H or -(Cl-C6)alkyl
• each R 8 is independently -(Cl-C6)alkyl, -(C3-Cl0)-cycloalkyl, (C6-Cl0)-aryl, or 5- to 10- membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0-5 R’; each R 10 is independently -(C3-Cl0)-cycloalkyl, 3- to 10- membered heterocyclyl-,
• each occurrence of R 10 is independently substituted with 0-5 R’; each R is independently selected from:
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2 , wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3- Cl0)cycloalkyl, or a 3- to 10- membered heterocyclyl;
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -NO2, -NCS, -CN, -CF 3 , -OCF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)-alkyl-, (C6-C10)- aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)-alkyl-, and (C6-C10)- aryl-0-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-3 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH2OR 0 , -CH2NR 0
• R° is independently selected from: -(Cl-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, and (C6-Cl0)-aryl-.
• the present invention provides a compound of formula I:
• A is C, CR 6 , or N;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
• D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• n R 2 is independently substituted with 0-5 R’;
• n and n are independently integers selected from 0-4;
• p is an integer selected from 2-4;
• each occurrence of the bond“ ” is either a single bond or a double bond
• each occurrence of R 1 , R 2 , R 4 , and R 5 are each independently selected from: halogen, -R, -OR, -N0 2 , -NCS, -CN, -CF 3 , -OCF 3 , -S1R3, -N(R) 2 , -SR, -SOR,
• R 3 is absent or is selected from:
• each R 6 is independently -H or -(Cl-C6)alkyl
• each R 7 is independently -H or -(Cl-C6)alkyl
• each R 8 is independently -(Cl-C6)alkyl, -(C3-Cl0)-cycloalkyl, (C6-Cl0)-aryl, or 5- to 10- membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0-5 R’; each R 10 is independently -(C3-Cl0)-cycloalkyl, 3- to 10- membered heterocyclyl-,
• each occurrence of R 10 is independently substituted with 0-5 R’; each R is independently selected from:
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2 , wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3- Cl0)cycloalkyl, or a 3 - to 10- membered heterocyclyl; wherein each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -NO2, -NCS, -CN, -CF 3 , -OCF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, (C3- C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6- Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)-alkyl-, (C6-ClO)-aryl-(Cl-C6)- alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)-alkyl-, and (C6-ClO)-aryl-0-(Cl- C6)-alkyl-. [0122]
• A is C, CR 6 , or N;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
• D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• n are each independently an integer selected from 0-4;
• each occurrence of the bond“ ” is either a single bond or a double bond
• R 1 , R 2 , R 4 , and R 5 are each independently selected from:
• R 3 is absent or is selected from:
• each R 6 is independently -H or -(Cl-C6)alkyl
• each R 7 is independently -H or -(Cl-C6)alkyl
• each R 8 is independently -(Cl-C6)alkyl, -(C3-Cl0)-cycloalkyl, (C6-Cl0)-aryl, or 5- to 10- membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0-5 R’;
• each R is independently selected from:
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N
• the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non- aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2 , wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3- Cl0)cycloalkyl, or a 3 - to 10- membered heterocyclyl;
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -NO2, -NCS, -CN, -CF 3 , -OCF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, (C3- C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6- Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)-alkyl-, (C6-ClO)-aryl-(Cl-C6)- alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)-alkyl-, and (C6-Cl0)-aryl-O-(Cl-C6)- alkyl-.
• A is C, CR 6 , or N;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
• D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• n and n are independently integers selected from 0-4;
• p is an integer selected from 2-4;
• each occurrence of the bond“ ” is either a single bond or a double bond
• each R 1 is independently selected from: halogen, -R, and -OR;
• R 2 is selected from: halogen, -R and -(CR 2 ) I -3-OR;
• R 3 is selected from: -R and -CN;
• R 4 and R 5 are each independently -H or -(Cl-C6)alkyl
• each R 6 is independently -H or -(Cl-C6)alkyl
• each R 7 is independently -H or -(Cl-C6)alkyl
• each R 8 is independently -(Cl-C6)alkyl, -(C3-Cl0)-cycloalkyl, (C6-Cl0)-aryl, or 5- to 10- membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0-5 R’; each R is independently selected from:
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• each occurrence of R is independently substituted with 0-5 R’; or when two R groups bound to the same atom, the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2 , wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3-
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -N0 2 , -NCS, -CN, -CF 3 , -0CF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)- alkyl-, (C6-ClO)-aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)- alkyl-, and (C6-Cl0)-aryl-O-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-5 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH 2 OR°, -CH 2 N(R°) 2 , -C(0)N
• A is C, CR 6 , or N;
• B and F are each independently selected from C, CR 6 , and N, wherein B and F cannot both be N;
• D is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• E is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• W is N, NR 7 , CR 6 or C(R 6 ) 2 ;
• X is N, NR 7 , O, CR 6 or C(R 6 ) 2 ;
• Y and Z are each independently selected from C, CR 6 , and N, wherein Y and Z cannot both be N;
• V is C or CR 6 .
• R 8 is independently - (Cl-C6)alkyl or (C6-Cl0)-aryl (e.g., phenyl), and wherein R 2 is independently substituted with 0-5 R’;
• m and n are independently integers selected from 0-4 (in some embodiments, m is 1);
• p is an integer selected from 2-4;
• each occurrence of the bond“ ” is either a single bond or a double bond
• each R 1 is independently selected from: -Cl, -F, -OMe, and -CoCH;
• R 2 is halogen, -(CR 2 ) I -3-OR, wherein each occurrence of R is independently selected from -H, -(Cl-C6)alkyl, (C6-Cl0)-aryl- (e.g., phenyl), and (C6-ClO)-aryl-(Cl- Cl2)aliphatic- (e.g., phenyl-(Cl-C6)alkyl-), and wherein each occurrence of R is independently substituted with 0-5 R’;
• R 3 is selected from: -CN, -CoCH, -CoC-(Cl-C6)alkyl, -CoC-phenyl, , wherein R 3 is substituted with 0-5 R’;
• each occurrence of R 4 and R 5 is independently -H or -(Cl-C6)alkyl
• each R 6 is independently -H or -(Cl-C6)alkyl
• each R 7 is independently -H or -(Cl-C6)alkyl; wherein each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)0R”, -N0 2 , -NCS, -CN, -CF 3 , -0CF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)- alkyl-, (C6-ClO)-aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)- alkyl-, and (C6-Cl0)-aryl-O-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-5 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH 2 OR°, -CH 2 NR°2, -C(0)N(R°)
• R 3 is selected from:
• each occurrence of R is independently selected from -(Cl-C6)-alkyl (e.g., linear or branched), -CoCH, phenyl, thiophene, (5- to 10- membered heteroaryl)-(Cl- C6)-alkyl-, (C6-ClO)-aryl-(Cl-C6)-alkyl-, wherein each R” is independently substituted with 0-3 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH 2 OR°, - CH 2 NR° 2 , -C(0)N(R°) 2 , -C(0)OR°, -N0 2 , -NCS, -CN, -CF 3 , -OCF3 and -N(R°) 2 , wherein each occurrence of R° is independently selected from: -(Cl-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to
• X, Y, Z, V and W together form a 5-membered aromatic or non-aromatic ring having 1-4 nitrogen atoms, wherein said ring is substituted with 0-3 R 6 and 0-2 R 7 .
• X, Y, Z, V and W together form a 5-membered aromatic ring having 1-3 nitrogen atoms, wherein said ring is substituted with 0-2 R 6 and 0-1 R 7 .
• X, Y, Z, V and W form a ring that is selected from:
• X, Y, Z, V and W form a ring that is selected from:
• W is N. In some embodiments, W is N, and X, Y, Z, V and W form a ring that is selected from:
• W is N, and X, Y, Z, V and W form a ring that is selected from:
• the ring formed by X, Y, Z, V and W is:
• the ring formed by X, Y, Z, V and W is:
• the ring formed by X, Y, Z, V and W is selected from:
• the ring formed by X, Y, Z, V and W is selected from:
• the ring formed by X, Y, Z, V and W is: In some embodiments, the ring formed by X, Y, Z, V and W is:
• A, B, D, E and F together form a 5-membered aromatic or non-aromatic ring having 1-4 nitrogen atoms, wherein said ring is substituted with 0-3 R 6 and 0-2 R 7 .
• A, B, D, E and F together form a 5-membered aromatic ring having 1-3 nitrogen atoms, wherein said ring is substituted with 0-2 R 6 and 0-1 R 7 .
• A, B, D, E and F form a ring that is selected from:
• the ring formed by A, B, D, F and E is:
• the compound has a structure of formula II:
• the compound has a structure of formula III:
• the compound has a structure of formula IV:
• R 2 is -OR 8 , -SR 8 , or -(CH 2 )nOR 8 , wherein R 2 is
• R 2 is -OR 8 .
• R 2 is -(CH 2 )nOR 8 .
• the compound has a structure of formula IV:
• R 2 is -(CH 2 ) n O(CH 2 ) n R 8 , -(CH 2 ) P R 8 or -(CH 2 ) n N(R”)R 10 , wherein R 2 is independently substituted with 0-5 R’ and wherein m, n, p, R 1 , R 3 , R 4 , R 5 , R 6 , R 8 , R 10 , and R” are as defined herein.
• R 2 is
• each occurrence of R 1 is selected from: halogen, -R, -OR, -N0 2 , -CN, -CF 3 , -OCF 3 , -N(R) 2 ,
• each occurrence of R 1 is independently selected from: halogen, - H, -(Cl-C6)alkyl, -OH, -0((Cl-C6)alkyl), -NO 2 , -CN, -CF 3 , -OCF 3 , -NH 2 ,
• each occurrence of R 1 is independently selected from: -H, -F, -Cl, -Br, -OH, -Me, -Et, - OMe, -OEt, -N0 2 , -CN, -CF 3 , -OCF3, -NH 3 ⁇ 4 -NMe 2 , -NEt 2 , -NHS0 2 Me, and -NHS0 2 Et.
• at least one R 1 is -OR.
• the at least one R 1 is -0((Cl-C6)alkyl), such as -OMe.
• R 2 is selected from: halogen, -R, -OR, -N0 2 , -(CR 2 ) I-3 R, -(CR 2 ) I-3 -OR, -CN, -CF3, -C(0)NR 2 , -C(0)OR, and -OCF3, wherein each occurrence of R is independently substituted with 0-5 R’.
• R 2 is selected from:
• R 2 is selected from: -H, -Me, -Et, propyl, isopropyl, butyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CF 3 , -C(0)OMe, -C(0)OEt, -OMe, -CEhOMe, -CEhOEt, -CH 2 OPh, -CH 2 -pyrrolidine, -CH 2 -morpholine, -CH 2 -pyridine, and -CHiPh, wherein said R 2 is substituted with 0-3 R’.
• R 2 is -Me substituted with 0-3 R’ selected from -R”, -OR”, oxo, -CEhOR”, - CH 2 NR” 2 , -C(0)N(R”)2, -C(0)OR”, -N0 2 , -NCS, -CN, -CF 3 , -0CF3 and -N(R”) 2 , wherein R” is independently selected from H, -(Cl-C6)-alkyl, (C6-Cl0)-aryl-, and (C6- ClO)-aryl-(Cl-C6)-alkyl-.
• R 2 is -Me that is independently substituted with 0-3 R’ selected from -N(Me) 2 , -N(Et) 2 and -N(Me)(CH 2 Ph).
• R 2 is selected from: -CEhPh, -CH 2 CH 2 Ph, -Ph, -OCH 2 Ph, -CH 2 OPh, -OCH 2 CH 2 Ph, -CH 2 CH 2 OPh, -CH 2 - pyrrolidine, -CEh-morpholine, -CH 2 -pyridine, and -CHiPh wherein said Ph, pyrrolidine, pyridine or morpholine is substituted with 0-5 R’.
• R 2 is selected from: -CEhPh, -ChbChbPh, -Ph, -OCEbPh, - CEhOPh, -OCH 2 CH 2 Ph, -CH 2 CH 2 OPh, -CH 2 -pyrrolidine, -CH 2 -morpholine, -CH 2 - pyridine, and -CHiPh, wherein said Ph, pyrrolidine, pyridine or morpholine is substituted with 0-5 R’ independently selected from halogen, (Cl-C6)-alkyl, -OH, -0((Cl-C6)- alkyl), -CH 2 OH, -CH 2 0(Cl-C6)-alkyl), -CH 2 N(Cl-C6)-alkyl) 2 , -C(0)0(Cl-C6)-alkyl), -C(0)N(Cl-C6)-alkyl)2,
• the -Ph, pyrrolidine, pyridine or morpholine of R 2 is substituted with 0-5 R’ independently selected from -F, -Cl, -CN, -Me, -Et, -OMe, and -OEt.
• R 2 is -CH 2 Ph,-CH 2 0Ph, -CH 2 - pyridine, -CH 2 -pyrrolidine, or -CH 2 -morpholine wherein said -Ph, pyrrolidine, pyridine or morpholine is substituted with 0-3 R’ independently selected from -F, -Cl, -CN, -Me, and -OMe.
• R 2 is -OR 8 , -SR 8 ,
• each R 8 is independently -(Cl-C6)alkyl, -(C3-Cl0)-cycloalkyl, (C6-Cl0)-aryl, or 5- to 10- membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0- 5 R’; n is an integer selected from 0-4; p is an integer selected from 2-4; and each R 10 is independently -(C3-Cl0)-cycloalkyl, 3- to 10- membered heterocyclyl-, (C6-Cl0)-aryl, or 5- to 10- membered heteroaryl, wherein each occurrence of R 10 is independently substituted with 0-5 R’.
• R 2 is OR 8 . In some embodiments, R 2 is OR 8 , wherein R 8 is (C6-Cl0)-aryl, substituted with 0-5 R’. In some embodiments, R 2 is OR 8 , wherein R 8 is (C6-Cl0)-aryl, substituted with 0-3 halogen (such as -F). In some embodiments, R 2 is -(CH 2 )nOR 8 or -(CH2) n O(CH2) n R 8 .
• R 2 is -(CFh) n OR 8 or -(CH2) n O(CH2) n R 8 , wherein R 8 is -(Cl-C6)alkyl, (C6-Cl0)-aryl, or 5- to 10- membered heteroaryl, wherein each occurrence of R 8 is independently substituted with 0-5 R’.
• R 3 is selected from: halogen, -R, -CN, -CF 3 , -SO2R, -C(0)N(R) 2 , -C(0)R and -C(0)OR, wherein each occurrence of R is independently substituted with 0-5 R’.
• R 3 is selected from: -F, -Br, -Cl, -(Cl-C6)alkyl, -CN, -CoC, -CF 3 , -S0 2 ((Cl- C6)alkyl), -C(0)N((Cl-C6)alkyl) 2 , -C(0)NH 2 , -C(0)((Cl-C6)alkyl),
• R 3 is selected from: -H, -C(0)OMe, -C(0)Et, -C(0)NMe 2 , -C(0)NH 2 , -C(0)OEt, -C(0)OCH 2 (/er/-butyl), -C(0)0CH 2 CF 3 , -C(0)0(isopropyl),-C(0)NEt 2 ,-CHF 2 , -CN, -CoC, -S0 2 Me, -S0 2 Et, -S0 2 Ph(Me), -CF 3 , -CHF 2 , -Me, -Et, -Br, -Cl, -CH 2 Ph,
• R 9 is selected from -H, -Me, -Et, -CF 3 , isopropyl, -OMe, -OEt, -O-isopropyl, -CH 2 NMe 2 , -tert- butyl and cyclopropyl.
• R 3 is -C(0)0Me or -C(0)0Et. In certain embodiments of a compound of formula I, II, III, or IV, R 3 is -C(0)0Me or -C(0)0Et. In certain embodiments of a compound of formula I, II, III, or
• R is selected from -H
• R 4 and R 5 are each independently selected from -H, halogen and -R, wherein each occurrence of R is independently substituted with 0-5 R’, or R 4 and R 5 may be taken together with the carbon atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-3 additional heteroatoms independently selected from N, O, S, SO, and S0 2 , wherein said ring is substituted with 0-5 R ⁇
• R 4 and R 5 are each independently selected from -H, -Me, -Et, -F, or R 4 and R 5 are taken together with the carbon atom to which they are bound to form a 3- to 8-membered aliphatic ring.
• both R 4 and R 5 are -H.
• the present invention provides a compound of formula II:
• n 0-3 (e.g., m is 1);
• each R 1 is independently selected from: -Cl, -F, -OMe, and -CoCH;
• R 2 is halogen, -(CR 2 ) I -3-OR, or -(CR 2 ) I.3 -0(CR 2 ) I.3 -R, wherein each occurrence of R is independently selected from -H, -(Cl-C6)alkyl, (C6-Cl0)-aryl- (e.g., phenyl), or 5- to
• R 3 is selected from: -CN, -CoCH, -CoC-(Cl-C6)alkyl, -CoC-phenyl, -COOMe, -COOEt, -(Cl-C6)alkyl,
• R 3 is substituted with 0-5 R’
• each occurrence of R 4 and R 5 is independently -H or -(Cl-C6)alkyl
• each R 6 is independently -H or -(Cl-C6)alkyl; wherein each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)0R”, -N0 2 , -NCS, -CN, -CF 3 , -0CF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)- alkyl-, (C6-ClO)-aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)- alkyl-, or (C6-Cl0)-aryl-O-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-5 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH 2 OR°, -CH 2 N(R°) 2 , -C(0)N
• R 1 is -Cl.
• R 3 is selected from:
• each occurrence of R 1 is independently selected from: halogen, -R°, -OR 0 , oxo, -CH 2 OR°, -CH 2 N(R°) 2 , -C(0)N(R°) 2 , -C(0)OR°, -N0 2 , -NCS, -CN, -CF 3 , -0CF3 and -N(R°) 2 , wherein each occurrence of R° is independently selected from: -(C1-C6)- aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, and (C6-Cl0)-aryl-.
• R 3 is selected from:
• R 1 is independently selected from: halogen, -R°, -OR 0 , oxo,
• R° is independently selected from: -(C1-C6)- aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, and (C6-Cl0)-aryl-, and R 2 is -(CH 2 ) n OR 8 , wherein R 8 is -(Cl-C6)alkyl (e.g., -Me, -Et, -propyl, or -isopropyl) wherein R 2 is independently substituted with 0-5 R’.
• R 8 is -(Cl-C6)alkyl (e.g., -Me, -Et, -propyl, or -isopropyl) wherein R 2 is independently substituted with 0-5 R’.
• R 3 is selected from:
• R 3 is selected from:
• R 2 is -(CH 2 ) n OR 8 , wherein R 8 is -(Cl-C6)alkyl (e.g., -Me, -Et, -propyl, or -isopropyl).
• R 3 is selected from:
• R 3 is selected from:
• R 2 is -(CH 2 ) n OR 8 , wherein R 8 is -(Cl-C6)alkyl (e.g., -Me, -Et, -propyl, or -isopropyl).
• R 2 is -(CEh)nOR 8 or -(CH2) n O(CH2) n R 8 , wherein each occurrence of R 8 is independently (C6-Cl0)-aryl (e.g., phenyl) or 5- to 10- membered heteroaryl- (e.g., pyridyl) and wherein R 2 is independently substituted with 0-5 R’.
• R 8 is independently (C6-Cl0)-aryl (e.g., phenyl) or 5- to 10- membered heteroaryl- (e.g., pyridyl) and wherein R 2 is independently substituted with 0-5 R’.
• R 2 is -(CEh)nOR 8 or -(CH2) n O(CH2) n R 8 , wherein each occurrence of R 8 is independently (C6-Cl0)-aryl (e.g., phenyl) or 5- to 10- membered heteroaryl- (e.g., pyridyl) and wherein R 2 is independently substituted with 0-5 R’, and R 3 is selected from: -CN, -CoCH, -CoC-(Cl-C6)alkyl, -COOMe, -COOEt, -(Cl-C6)alkyl, , wherein R 3 is substituted with 0-3 R’.
• R 3 is selected from: -CN, -CoCH, -CoC-(Cl-C6)alkyl, -COOMe, -COOEt, -(Cl-C6)alkyl, wherein R 3 is substituted with 0-3 R’.
• R 2 is -CEhOR 8 or -CH2OCH2R 8 , wherein each occurrence of R 8 is independently (C6-Cl0)-aryl (e.g., phenyl) or 5- to 10- membered heteroaryl- (e.g., pyridyl) and wherein R 2 is independently substituted with 0-5 R’; and R 3 is selected from: -CoCH, -CoC-(Cl-C6)alkyl, H s J // 0 // 0 s / ' N
• R 3 is substituted with 0-2 R’ (e.g., R 3 is unsubstituted).
• the present invention provides a compound of formula II:
• each R 1 is independently selected from: -Cl, -F, -OMe, and -C ⁇ CH;
• R 2 is halogen or -(CR 2 ) I -3-OR, wherein each occurrence of R is independently selected from -H, -(Cl-C6)alkyl, (C6-Cl0)-aryl- (e.g., phenyl), and (C6-ClO)-aryl-(Cl- Cl2)aliphatic- (e.g., phenyl-(Cl-C6)alkyl-), and wherein each occurrence of R is independently substituted with 0-5 R’;
• R 3 is selected from: -CN, -C ⁇ CH, -C ⁇ C-(Cl-C6)alkyl, -C ⁇ C-phenyl, , wherein R 3 is substituted with 0-5 R’;
• each occurrence of R 4 and R 5 is independently -H or -(Cl-C6)alkyl
• each R 6 is independently -H or -(Cl-C6)alkyl
• each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)OR”, -N0 2 , -NCS, -CN, -CF 3 , -0CF3 and -N(R”) 2 ;
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, -(Cl- C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-Cl0)-aryl-, (5- to 10- membered heteroaryl)-(Cl-C6)- alkyl-, (C6-ClO)-aryl-(Cl-C6)-alkyl-, (5- to 10- membered heteroaryl)-0-(Cl-C6)- alkyl-, or (C6-Cl0)-aryl-O-(Cl-C6)-alkyl-, wherein each occurrence of R” is independently substituted with 0-5 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH 2 OR°, -CH 2 N(R°) 2 , -C(0)N
• R 3 is selected from:
• each occurrence of R is independently selected from -(Cl-C6)-alkyl (e.g., linear or branched), -CoCH, phenyl, thiophene, (5- to 10- membered heteroaryl)-(Cl- C6)-alkyl-, and (C6-ClO)-aryl-(Cl-C6)-alkyl-, wherein each R” is independently substituted with 0-3 substituents selected from: halogen, -R°, -OR 0 , oxo, -CH 2 OR°, -
• R° is independently selected from: -(Cl-C6)-aliphatic, (C3-C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, and (C6-Cl0)-aryl-.
• n 0-3;
• each R 1 is independently selected from: halogen (e.g., Cl, F), -H, -(Cl-C6)alkyl, -OH, -0((Cl-C6)alkyl) (e.g., -OMe), -N0 2 , -CN, -CF 3 , and -OCF 3 , wherein R 1 is independently substituted with 0-5 R’;
• R 2 is selected from:
• R 2 is independently substituted with 0-5 R’;
• R 3 is selected from:
• heterocyclyl such as an optionally substituted wherein R 3 is independently substituted with 0-5 R’; R 4 and R 5 are each independently selected from -H, halogen and -(Cl-C6)alkyl;
• R 6 is selected from -H and -(Cl-C6)alkyl
• each R is independently selected from:
• heterocyclyl has 1-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2
• said heteroaryl has 1-4 heteroatoms independently selected from N, NH, O, and S;
• the two R groups may be taken together with the atom to which they are bound to form a 3- to lO-membered aromatic or non aromatic ring having 0-4 heteroatoms independently selected from N, NH, O, S, SO, and S0 2 , wherein said ring is optionally substituted with 0-5 R’, and wherein said ring is optionally fused to a (C6-Cl0)aryl, 5- to 10- membered heteroaryl, (C3- Cl0)cycloalkyl, or a 3 - to 10- membered heterocyclyl; wherein each occurrence of R’ is independently selected from halogen, -R”, -OR”, oxo, -CH2OR”, -CH 2 NR” 2 , -C(0)N(R”) 2 , -C(0)0R”, -N0 2 , -NCS, -CN, -CF 3 , -0CF3 and -N(R”) 2
• each occurrence of R is independently selected from H, -(Cl-C6)-alkyl, (C3- C6)-cycloalkyl, 3- to 6- membered heterocyclyl, 5- to 10- membered heteroaryl-, (C6-
• the present invention provides a compound of formula II:
• n 0-3;
• each R 1 is independently selected from: halogen (e.g., Cl, F), -H, -(Cl-C6)alkyl, -OH, -0((Cl-C6)alkyl) (e.g., -OMe), -N0 2 , -CN, -CF 3 , and -OCF3, wherein R 1 is independently substituted with 0-5 R’;
• R 2 is selected from:
• R 3 is selected from:
• C6)alkyl 2 , -C(0)NH 2 , -C(0)0((Cl-C6)alkyl), -C(0)((Cl-C6)alkyl), -(C6-Cl0)aryl,
• 5- to 10- membered heteroaryl e.g., 5-membered heteroaryl such as an optionally substituted
• 5- to 10- membered heterocyclyl e.g., 5-membered
• heterocyclyl such as an optionally substituted wherein R 3 is independently substituted with 0-5 R’;
• R 4 and R 5 are each -H, halogen and -(Cl-C6)alkyl
• R 6 is selected from -H and -(Cl-C6)alkyl
• each R is independently selected from:

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Psychiatry (AREA)
• Psychology (AREA)
• Hospice & Palliative Care (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=68984202

Family Applications (1)

Country Status (11)

Cited By (8)

Families Citing this family (3)

Citations (5)

Family Cites Families (78)

• 2019
  • 2019-06-19 US US16/445,854 patent/US11414425B2/en active Active
  • 2019-06-19 MX MX2020013927A patent/MX2020013927A/es unknown
  • 2019-06-19 CN CN201980053122.8A patent/CN112601749B/zh active Active
  • 2019-06-19 CA CA3104478A patent/CA3104478A1/en active Pending
  • 2019-06-19 AU AU2019288382A patent/AU2019288382B2/en active Active
  • 2019-06-19 EA EA202190076A patent/EA202190076A1/ru unknown
  • 2019-06-19 IL IL279530A patent/IL279530B2/en unknown
  • 2019-06-19 JP JP2020571354A patent/JP7514534B2/ja active Active
  • 2019-06-19 BR BR112020026062-2A patent/BR112020026062B1/pt not_active IP Right Cessation
  • 2019-06-19 EP EP19822528.6A patent/EP3810611A4/en active Pending
  • 2019-06-19 WO PCT/US2019/038038 patent/WO2019246300A1/en not_active Ceased
• 2022
  • 2022-06-27 US US17/850,144 patent/US12291535B2/en active Active

Patent Citations (5)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events